---
layout: post
title: 中國應該適當調整疫苗政策
date: 2021-06-08 04:25:48.000000000 +00:00
link: https://matters.news/@WilliamLeung/%25E4%25B8%25AD%25E5%259C%258B%25E6%2587%2589%25E8%25A9%25B2%25E9%2581%25A9%25E7%2595%25B6%25E8%25AA%25BF%25E6%2595%25B4%25E7%2596%25AB%25E8%258B%2597%25E6%2594%25BF%25E7%25AD%2596-bafyreidwwcxnb5kj7bkl4unfie4ccduh3alpnkadseo4bgs3qs25zz7nem
categories: matters
tags: blog
author: William
---

<p>Sinovac/CoronaVac （科興）和 Sinopharm/BBIBP （國藥）是中國國產的兩款針對新冠肺炎的滅活疫苗，也是在世界上被廣泛應用的疫苗之二，目前都已被WHO批准緊急使用。這兩款滅活疫苗的優缺點都非常明顯。其優點是製作技術相對簡易，可以常溫保存不需要冷凍，且能有效減少染病後的重症和死亡率，在疫苗緊缺的時候，可以極大緩解醫療資源的壓力。但其缺點也很明顯，即有效率相對使用其他技術的疫苗偏低，對高危人群尤其是老人和有基礎疾病的人群的安全性以及有效性仍然值得懷疑。</p><p>科興是最早公布其三期試驗中期數據的中國疫苗公司。早在今年一月份，巴西就<a href="https://www.bloomberg.com/news/articles/2021-01-12/china-vaccine-going-global-with-four-different-efficacy-rates" target="_blank">公布</a>了其在科興疫苗的三期試驗中期報告，顯示其有預防感染的效率為50.38%，其中對輕症的預防效力為78%，對重症的預防效力為100%。在四月份時，巴西<a href="https://www.reuters.com/business/healthcare-pharmaceuticals/brazil-sees-1803-covid-19-deaths-chinese-vaccine-found-507-effective-against-2021-04-11/" target="_blank">公布</a>了最終報告，修正其有效率為50.7%，對輕症的預防效力為83%。在巴西的實驗結果公布前後，科興疫苗在其他國家得到了更高的有效率，但由於這些實驗相對巴西實驗來講實驗規模相對較小，故準確性存疑。之後，針對科興疫苗在真實世界的有效率研究相繼展開。</p><p>比如巴西針對兩萬多名醫護人員做了科興疫苗的相關<a href="https://www.medrxiv.org/content/10.1101/2021.04.12.21255308v1" target="_blank">研究</a>，其結果基本吻合三期實驗結果，即有效率為50%左右。智利大學也針對科興疫苗的有效率做了一些研究，<a href="https://www.scmp.com/news/china/science/article/3128886/chile-covid-19-vaccination-drive-adds-sinovac-efficacy-data" target="_blank">發現</a>其有效率為56.5%，也和巴西的實驗結果基本吻合。不過智利大學發現，科興疫苗在接種一針後其效力僅為3%，完全接種後在兩個禮拜之內其有效率為27.7%，兩個禮拜後就會達到56.5%的有效率。智利政府也<a href="https://www.reuters.com/business/healthcare-pharmaceuticals/chinas-sinovac-covid-19-vaccine-67-effective-preventing-symptomatic-infection-2021-04-16/" target="_blank">公布</a>了一份報告，認為科興疫苗的效率達到67%，預防住院的有效率為85%，預防死亡的有效率為80%。其後在跟蹤印尼的醫護人員的<a href="https://www.bloomberg.com/news/articles/2021-05-11/china-s-sinovac-shot-found-highly-effective-in-real-world-study" target="_blank">研究中</a>，科興疫苗則表現出了極高的預防住院和預防死亡的有效率。種種研究證明，科興疫苗的有效率雖然僅僅過及格線，但它能有效預防住院和重症，死亡，對減輕醫療資源的壓力有極大幫助。</p><p>但是，從WHO<a href="https://cdn.who.int/media/docs/default-source/immunization/sage/2021/april/5_sage29apr2021_critical-evidence_sinovac.pdf" target="_blank">公布</a>的科興疫苗的綜合實驗結果來看，科興疫苗的缺點也很明顯。</p><figure class="image">
      <picture>
        <source type="image/webp" media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/525f6c47-d481-4197-8501-e622da86c4fd.webp" onerror="this.srcset='https://assets.matters.news/embed/525f6c47-d481-4197-8501-e622da86c4fd.png'">

        <source media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/525f6c47-d481-4197-8501-e622da86c4fd.png" onerror="this.srcset='https://assets.matters.news/embed/525f6c47-d481-4197-8501-e622da86c4fd.png'">

        <source type="image/webp" srcset="https://assets.matters.news/processed/540w/embed/525f6c47-d481-4197-8501-e622da86c4fd.webp">

        <img src="https://assets.matters.news/embed/525f6c47-d481-4197-8501-e622da86c4fd.png" srcset="https://assets.matters.news/processed/540w/embed/525f6c47-d481-4197-8501-e622da86c4fd.png" loading="lazy" referrerpolicy="no-referrer">
      </picture>
    <figcaption><span></span></figcaption></figure><figure class="image">
      <picture>
        <source type="image/webp" media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/85031f0a-1bbc-4626-a036-a419420900cf.webp" onerror="this.srcset='https://assets.matters.news/embed/85031f0a-1bbc-4626-a036-a419420900cf.png'">

        <source media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/85031f0a-1bbc-4626-a036-a419420900cf.png" onerror="this.srcset='https://assets.matters.news/embed/85031f0a-1bbc-4626-a036-a419420900cf.png'">

        <source type="image/webp" srcset="https://assets.matters.news/processed/540w/embed/85031f0a-1bbc-4626-a036-a419420900cf.webp">

        <img src="https://assets.matters.news/embed/85031f0a-1bbc-4626-a036-a419420900cf.png" srcset="https://assets.matters.news/processed/540w/embed/85031f0a-1bbc-4626-a036-a419420900cf.png" loading="lazy" referrerpolicy="no-referrer">
      </picture>
    <figcaption><span></span></figcaption></figure><p>科興的三期試驗sample十分不均衡，特別是針對老人和基礎疾病人群的實驗樣本相對於健康人群來講十分不足，這也是為什麼WHO的檢驗結果也突出強調他們對於科興疫苗在健康青壯年身上的作用十分有信心，但對於老人和有基礎疾病人群的有效性信心有限（Moderate level of confidence），對於安全性幾乎沒有信心（low level of confidence）。這也能解釋為什麼全世界大多數國家都是老人和有基礎疾病的人優先打疫苗，而中國則是青壯年人優先打疫苗。</p><figure class="image">
      <picture>
        <source type="image/webp" media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/d9c4699d-2f38-4e0b-af4e-ff69b9a0dc0b.webp" onerror="this.srcset='https://assets.matters.news/embed/d9c4699d-2f38-4e0b-af4e-ff69b9a0dc0b.png'">

        <source media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/d9c4699d-2f38-4e0b-af4e-ff69b9a0dc0b.png" onerror="this.srcset='https://assets.matters.news/embed/d9c4699d-2f38-4e0b-af4e-ff69b9a0dc0b.png'">

        <source type="image/webp" srcset="https://assets.matters.news/processed/540w/embed/d9c4699d-2f38-4e0b-af4e-ff69b9a0dc0b.webp">

        <img src="https://assets.matters.news/embed/d9c4699d-2f38-4e0b-af4e-ff69b9a0dc0b.png" srcset="https://assets.matters.news/processed/540w/embed/d9c4699d-2f38-4e0b-af4e-ff69b9a0dc0b.png" loading="lazy" referrerpolicy="no-referrer">
      </picture>
    <figcaption><span></span></figcaption></figure><p>截止6月4日，智利已經有44%的人口完成了全面接種，而至少接種一劑的人已經接近人口總數的百分之六十。但是，主要是接種科興疫苗的智利的感染人數一直未能明顯下降，一度在次封城。</p><figure class="image">
      <picture>
        <source type="image/webp" media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/946dbbc0-0bf4-436e-9ece-c12d46a2465d.webp" onerror="this.srcset='https://assets.matters.news/embed/946dbbc0-0bf4-436e-9ece-c12d46a2465d.png'">

        <source media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/946dbbc0-0bf4-436e-9ece-c12d46a2465d.png" onerror="this.srcset='https://assets.matters.news/embed/946dbbc0-0bf4-436e-9ece-c12d46a2465d.png'">

        <source type="image/webp" srcset="https://assets.matters.news/processed/540w/embed/946dbbc0-0bf4-436e-9ece-c12d46a2465d.webp">

        <img src="https://assets.matters.news/embed/946dbbc0-0bf4-436e-9ece-c12d46a2465d.png" srcset="https://assets.matters.news/processed/540w/embed/946dbbc0-0bf4-436e-9ece-c12d46a2465d.png" loading="lazy" referrerpolicy="no-referrer">
      </picture>
    <figcaption><span></span></figcaption></figure><p>結合以上可以看出，優缺點都很明顯的科興疫苗雖然可以有效緩解醫療資源的壓力，拯救生命，但因為其差強人意的有效率，無法強力控制病毒傳播，故無法完全結束疫情。</p><p>如果說科興是經過各國的研究檢驗，實驗數據豐富，坦坦蕩蕩的中國新冠疫苗的話，國藥疫苗就相對諱莫如深了。國藥疫苗雖然也早在各個國家開展三期試驗，但一直對其疫苗實驗結果的詳細數據遮遮掩掩。除了公布過幾個孤零零的有效率數字外，在申請WHO緊急授權之前，幾乎很難找到任何關於國藥疫苗的詳細實驗數據。不過早前國藥為了申請WHO緊急授權，終於<a href="https://cdn.who.int/media/docs/default-source/immunization/sage/2021/april/2_sage29apr2021_critical-evidence_sinopharm.pdf" target="_blank">公布</a>了疫苗實驗的詳細數據。仔細看看國藥的實驗數據，也就無怪乎國藥的實驗數據姍姍來遲了。</p><figure class="image">
      <picture>
        <source type="image/webp" media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/f32227d2-0b71-4acd-aa3f-c1ea79c03ce8.webp" onerror="this.srcset='https://assets.matters.news/embed/f32227d2-0b71-4acd-aa3f-c1ea79c03ce8.png'">

        <source media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/f32227d2-0b71-4acd-aa3f-c1ea79c03ce8.png" onerror="this.srcset='https://assets.matters.news/embed/f32227d2-0b71-4acd-aa3f-c1ea79c03ce8.png'">

        <source type="image/webp" srcset="https://assets.matters.news/processed/540w/embed/f32227d2-0b71-4acd-aa3f-c1ea79c03ce8.webp">

        <img src="https://assets.matters.news/embed/f32227d2-0b71-4acd-aa3f-c1ea79c03ce8.png" srcset="https://assets.matters.news/processed/540w/embed/f32227d2-0b71-4acd-aa3f-c1ea79c03ce8.png" loading="lazy" referrerpolicy="no-referrer">
      </picture>
    <figcaption><span></span></figcaption></figure><figure class="image">
      <picture>
        <source type="image/webp" media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/3b856579-dd44-4659-a811-7b99ddd2491b.webp" onerror="this.srcset='https://assets.matters.news/embed/3b856579-dd44-4659-a811-7b99ddd2491b.png'">

        <source media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/3b856579-dd44-4659-a811-7b99ddd2491b.png" onerror="this.srcset='https://assets.matters.news/embed/3b856579-dd44-4659-a811-7b99ddd2491b.png'">

        <source type="image/webp" srcset="https://assets.matters.news/processed/540w/embed/3b856579-dd44-4659-a811-7b99ddd2491b.webp">

        <img src="https://assets.matters.news/embed/3b856579-dd44-4659-a811-7b99ddd2491b.png" srcset="https://assets.matters.news/processed/540w/embed/3b856579-dd44-4659-a811-7b99ddd2491b.png" loading="lazy" referrerpolicy="no-referrer">
      </picture>
    <figcaption><span></span></figcaption></figure><p>如果說科興針對健康人群和基礎疾病人群，青壯年和老人的sampling已經嚴重失衡了，國藥針對基礎疾病和老人的實驗就只能用少得可憐來形容了。國藥的實驗更像是在理想狀態下的實驗，即主要參與的測試人群都是青壯年男性，且身體健康。在這樣的測試環境下，國藥的得出了一個78.1%的有效率和100%的防重症感染率。想必這也是為什麼WHO對於國藥疫苗的信心遠比科興更低的原因。因為WHO僅對國藥疫苗在健康青壯年身上的有效性有強烈信心，對他們的安全性就信心有限。對於老人和有基礎疾病人群的有效性和安全性，WHO是完全沒有信心（very low/low level of confidence ），用了三個very low level 來形容，而科興最多只被評為low level 而已。</p><figure class="image">
      <picture>
        <source type="image/webp" media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/3baa9a03-5a66-463f-b520-576df076f0f3.webp" onerror="this.srcset='https://assets.matters.news/embed/3baa9a03-5a66-463f-b520-576df076f0f3.png'">

        <source media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/3baa9a03-5a66-463f-b520-576df076f0f3.png" onerror="this.srcset='https://assets.matters.news/embed/3baa9a03-5a66-463f-b520-576df076f0f3.png'">

        <source type="image/webp" srcset="https://assets.matters.news/processed/540w/embed/3baa9a03-5a66-463f-b520-576df076f0f3.webp">

        <img src="https://assets.matters.news/embed/3baa9a03-5a66-463f-b520-576df076f0f3.png" srcset="https://assets.matters.news/processed/540w/embed/3baa9a03-5a66-463f-b520-576df076f0f3.png" loading="lazy" referrerpolicy="no-referrer">
      </picture>
    <figcaption><span></span></figcaption></figure><p>因此，雖然看起來國藥的數據要比科興漂亮很多，但實際上國藥在真實世界中展現出來的保護效力可能還不如科興。全球接種疫苗比例最高，甚至比以色列還要高一點的島國塞舌爾接種的疫苗一半以上都是國藥疫苗，但在如此高的接種比例下，早前甚至出現病例大幅上升，要再次封城的情況。而澳洲Mulholland博士根據塞舌爾的數據進行研究，<a href="https://www.nytimes.com/2021/05/12/business/economy/covid-seychelles-sinopharm.html" target="_blank">推斷</a>國藥疫苗的有效率應該只有50%而非78.1%。</p><figure class="image">
      <picture>
        <source type="image/webp" media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/ae2f0f18-9a20-446f-9964-07dec6f09dbf.webp" onerror="this.srcset='https://assets.matters.news/embed/ae2f0f18-9a20-446f-9964-07dec6f09dbf.png'">

        <source media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/ae2f0f18-9a20-446f-9964-07dec6f09dbf.png" onerror="this.srcset='https://assets.matters.news/embed/ae2f0f18-9a20-446f-9964-07dec6f09dbf.png'">

        <source type="image/webp" srcset="https://assets.matters.news/processed/540w/embed/ae2f0f18-9a20-446f-9964-07dec6f09dbf.webp">

        <img src="https://assets.matters.news/embed/ae2f0f18-9a20-446f-9964-07dec6f09dbf.png" srcset="https://assets.matters.news/processed/540w/embed/ae2f0f18-9a20-446f-9964-07dec6f09dbf.png" loading="lazy" referrerpolicy="no-referrer">
      </picture>
    <figcaption><span></span></figcaption></figure><p>同樣大量接種國藥疫苗的阿聯和巴林也對國藥疫苗的效力產生了懷疑，兩國都大量採購德國Pfizer BNT（復必泰）疫苗，並<a href="https://www.reuters.com/world/middle-east/uae-bahrain-make-pfizerbiontech-shot-available-those-who-got-sinopharm-vaccine-2021-06-03/" target="_blank">鼓勵</a>已經接種了國藥疫苗的國民再次接種復必泰，巴林更是直接<a href="https://www.washingtonpost.com/world/2021/06/03/bahrain-seychelles-sinopharm-vaccine/" target="_blank">講</a>打兩針國藥疫苗不足夠對抗風險。兩國此前為了加強國藥的有效力甚至還研<a href="https://www.washingtonpost.com/world/2021/05/19/uae-sinopharm-third-dose-booster/" target="_blank">究</a>過打第三針的方法。以上種種不得不讓人猜疑，早前秘魯一間大學的研究<a href="https://www.archyde.com/coronavirus-in-peru-minsa-clarifies-that-the-effectiveness-of-the-sinopharm-vaccine-against-covid-19-is-79-34/" target="_blank">稱</a>國藥疫苗的有效率僅有33%和11%的可信度了。雖然也有研究<a href="https://www.bloomberg.com/news/articles/2021-05-27/china-s-sinopharm-publishes-awaited-covid-vaccine-study-details" target="_blank">稱</a>國藥的疫苗有效率達72%，但從實際表現來看，國藥的疫苗確實讓人懷疑。</p><figure class="image">
      <picture>
        <source type="image/webp" media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/4008f17a-5415-4c20-8425-dc4429ccf9d2.webp" onerror="this.srcset='https://assets.matters.news/embed/4008f17a-5415-4c20-8425-dc4429ccf9d2.png'">

        <source media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/4008f17a-5415-4c20-8425-dc4429ccf9d2.png" onerror="this.srcset='https://assets.matters.news/embed/4008f17a-5415-4c20-8425-dc4429ccf9d2.png'">

        <source type="image/webp" srcset="https://assets.matters.news/processed/540w/embed/4008f17a-5415-4c20-8425-dc4429ccf9d2.webp">

        <img src="https://assets.matters.news/embed/4008f17a-5415-4c20-8425-dc4429ccf9d2.png" srcset="https://assets.matters.news/processed/540w/embed/4008f17a-5415-4c20-8425-dc4429ccf9d2.png" loading="lazy" referrerpolicy="no-referrer">
      </picture>
    <figcaption><span></span></figcaption></figure><p><br></p><figure class="image">
      <picture>
        <source type="image/webp" media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/69bc0c11-942a-4ad4-aa06-9dbbac092fb0.webp" onerror="this.srcset='https://assets.matters.news/embed/69bc0c11-942a-4ad4-aa06-9dbbac092fb0.png'">

        <source media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/69bc0c11-942a-4ad4-aa06-9dbbac092fb0.png" onerror="this.srcset='https://assets.matters.news/embed/69bc0c11-942a-4ad4-aa06-9dbbac092fb0.png'">

        <source type="image/webp" srcset="https://assets.matters.news/processed/540w/embed/69bc0c11-942a-4ad4-aa06-9dbbac092fb0.webp">

        <img src="https://assets.matters.news/embed/69bc0c11-942a-4ad4-aa06-9dbbac092fb0.png" srcset="https://assets.matters.news/processed/540w/embed/69bc0c11-942a-4ad4-aa06-9dbbac092fb0.png" loading="lazy" referrerpolicy="no-referrer">
      </picture>
    <figcaption><span></span></figcaption></figure><p>相對應的，目前被全世界公認為最好的Pfizer BNT （復必泰）新冠疫苗的三期試驗就相對均衡，顧及到了性別，年齡，基礎疾病等因素。在此環境下，復必泰的實驗有效率為94%，可以說是極為優秀。也正是其三期試驗包含了足夠多的老人和基礎疾病人群，才使大多數使用復必泰的國家敢於優先給老人施打而非青壯年。</p><figure class="image">
      <picture>
        <source type="image/webp" media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/21913fd3-38d5-40cf-a9dc-881a66b41f0d.webp" onerror="this.srcset='https://assets.matters.news/embed/21913fd3-38d5-40cf-a9dc-881a66b41f0d.png'">

        <source media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/21913fd3-38d5-40cf-a9dc-881a66b41f0d.png" onerror="this.srcset='https://assets.matters.news/embed/21913fd3-38d5-40cf-a9dc-881a66b41f0d.png'">

        <source type="image/webp" srcset="https://assets.matters.news/processed/540w/embed/21913fd3-38d5-40cf-a9dc-881a66b41f0d.webp">

        <img src="https://assets.matters.news/embed/21913fd3-38d5-40cf-a9dc-881a66b41f0d.png" srcset="https://assets.matters.news/processed/540w/embed/21913fd3-38d5-40cf-a9dc-881a66b41f0d.png" loading="lazy" referrerpolicy="no-referrer">
      </picture>
    <figcaption><span></span></figcaption></figure><figure class="image">
      <picture>
        <source type="image/webp" media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/bc55b64a-1b01-4e85-ae7f-34399852030b.webp" onerror="this.srcset='https://assets.matters.news/embed/bc55b64a-1b01-4e85-ae7f-34399852030b.png'">

        <source media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/bc55b64a-1b01-4e85-ae7f-34399852030b.png" onerror="this.srcset='https://assets.matters.news/embed/bc55b64a-1b01-4e85-ae7f-34399852030b.png'">

        <source type="image/webp" srcset="https://assets.matters.news/processed/540w/embed/bc55b64a-1b01-4e85-ae7f-34399852030b.webp">

        <img src="https://assets.matters.news/embed/bc55b64a-1b01-4e85-ae7f-34399852030b.png" srcset="https://assets.matters.news/processed/540w/embed/bc55b64a-1b01-4e85-ae7f-34399852030b.png" loading="lazy" referrerpolicy="no-referrer">
      </picture>
    <figcaption><span></span></figcaption></figure><p>因此WHO對其的評價<a href="https://cdn.who.int/media/docs/default-source/immunization/sage/2021/january/4-evidence-assessment5-jan-2021-final.pdf?sfvrsn=cf627b70_9" target="_blank">是</a>，“There were no other specific safety concerns identified in subgroup analyses by age, race, ethnicity, medical comorbidities, or prior SARS-CoV-2 infection. Common concerns include the speed of development, the lack of long-term safety data, conspiracy theories (”mRNA vaccines may genetically modify humans”) and unsubstantiated rumors.” 相對於中國國產疫苗的各種very low level of confidence來講，WHO對復必泰的擔憂更多還是在“Higher delivery cost” 和“Operational complexity may impact access“會導致的生產能力問題，而對其用於不同年齡，不同性別，不同種族乃至有基礎疾病人群的安全性都很有信心。目前所有新冠疫苗問世未久，缺乏長期性的數據，復必泰也不例外。</p><p>復必泰疫苗在實際使用中也表現出了極高的質素和防止病毒傳染的有效率，比如在進一步的實際<a href="https://www.businesswire.com/news/home/20210401005365/en/" target="_blank">研究</a>中，完成接種後的六個月內，復必泰的有效率仍然高達91.3%。美國不同部門認為它的預防重症感染率為95.3%和100%。在變異病毒肆虐的南非，復必泰甚至表現出了100%的有效率。在以色列的實際施打<a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00947-8/fulltext" target="_blank">研究</a>中，復必泰同樣表現出極高的有效率，應對各種情況和不同病毒都有9成以上的效力。而主要施打復必泰的以色列也早早解除了封鎖狀態，回歸了正常生活，且病毒仍然無法大肆傳播，每天新增的案例也來到了個位數。這無疑和主要施打中國國產疫苗且施打率並不明顯低於以色列的國家的疫情形成了鮮明的對比。</p><figure class="image">
      <picture>
        <source type="image/webp" media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/99df2d23-5ee8-4ff3-8629-f5d80ae96eb5.webp" onerror="this.srcset='https://assets.matters.news/embed/99df2d23-5ee8-4ff3-8629-f5d80ae96eb5.png'">

        <source media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/99df2d23-5ee8-4ff3-8629-f5d80ae96eb5.png" onerror="this.srcset='https://assets.matters.news/embed/99df2d23-5ee8-4ff3-8629-f5d80ae96eb5.png'">

        <source type="image/webp" srcset="https://assets.matters.news/processed/540w/embed/99df2d23-5ee8-4ff3-8629-f5d80ae96eb5.webp">

        <img src="https://assets.matters.news/embed/99df2d23-5ee8-4ff3-8629-f5d80ae96eb5.png" srcset="https://assets.matters.news/processed/540w/embed/99df2d23-5ee8-4ff3-8629-f5d80ae96eb5.png" loading="lazy" referrerpolicy="no-referrer">
      </picture>
    <figcaption><span></span></figcaption></figure><p>同樣使用mRNA技術的美國疫苗Moderna其表現也毫不遜色於復必泰。其樣本分佈相對均衡，三期試驗的有效性也<a href="https://www.fda.gov/media/144434/download" target="_blank">達到了</a>驚人的94.1%，即使只打一針的有效率也有50.8%。WHO也給了較高的<a href="https://cdn.who.int/media/docs/default-source/immunization/sage/2021/january/3-evidence-assessment_covid19_moderna_revised_final.pdf?sfvrsn=61ab4400_8" target="_blank">評價</a>。實際的最終<a href="https://www.wilx.com/2021/04/15/new-moderna-vaccine-data-shows-95-efficacy-rate/" target="_blank">研究</a>中，Moderna也表現出90%的有效率和95%防重症感染率。</p><figure class="image">
      <picture>
        <source type="image/webp" media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/86d71982-699e-4154-a178-c13852e30ccc.webp" onerror="this.srcset='https://assets.matters.news/embed/86d71982-699e-4154-a178-c13852e30ccc.png'">

        <source media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/86d71982-699e-4154-a178-c13852e30ccc.png" onerror="this.srcset='https://assets.matters.news/embed/86d71982-699e-4154-a178-c13852e30ccc.png'">

        <source type="image/webp" srcset="https://assets.matters.news/processed/540w/embed/86d71982-699e-4154-a178-c13852e30ccc.webp">

        <img src="https://assets.matters.news/embed/86d71982-699e-4154-a178-c13852e30ccc.png" srcset="https://assets.matters.news/processed/540w/embed/86d71982-699e-4154-a178-c13852e30ccc.png" loading="lazy" referrerpolicy="no-referrer">
      </picture>
    <figcaption><span></span></figcaption></figure><p><br></p><figure class="image">
      <picture>
        <source type="image/webp" media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/34d88500-eaa3-4a2e-9a44-e16337f98164.webp" onerror="this.srcset='https://assets.matters.news/embed/34d88500-eaa3-4a2e-9a44-e16337f98164.png'">

        <source media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/34d88500-eaa3-4a2e-9a44-e16337f98164.png" onerror="this.srcset='https://assets.matters.news/embed/34d88500-eaa3-4a2e-9a44-e16337f98164.png'">

        <source type="image/webp" srcset="https://assets.matters.news/processed/540w/embed/34d88500-eaa3-4a2e-9a44-e16337f98164.webp">

        <img src="https://assets.matters.news/embed/34d88500-eaa3-4a2e-9a44-e16337f98164.png" srcset="https://assets.matters.news/processed/540w/embed/34d88500-eaa3-4a2e-9a44-e16337f98164.png" loading="lazy" referrerpolicy="no-referrer">
      </picture>
    <figcaption><span></span></figcaption></figure><p>大量使用Moderna以及復必泰疫苗的美國，也因此控制住了疫情，使其單日確診人數連續下跌，從單日三十萬人的確診數回落到如今的一萬多人。</p><figure class="image">
      <picture>
        <source type="image/webp" media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/65e1c421-0e20-4885-8d2f-db4606734aa7.webp" onerror="this.srcset='https://assets.matters.news/embed/65e1c421-0e20-4885-8d2f-db4606734aa7.png'">

        <source media="(min-width: 768px)" srcset="https://assets.matters.news/processed/1080w/embed/65e1c421-0e20-4885-8d2f-db4606734aa7.png" onerror="this.srcset='https://assets.matters.news/embed/65e1c421-0e20-4885-8d2f-db4606734aa7.png'">

        <source type="image/webp" srcset="https://assets.matters.news/processed/540w/embed/65e1c421-0e20-4885-8d2f-db4606734aa7.webp">

        <img src="https://assets.matters.news/embed/65e1c421-0e20-4885-8d2f-db4606734aa7.png" srcset="https://assets.matters.news/processed/540w/embed/65e1c421-0e20-4885-8d2f-db4606734aa7.png" loading="lazy" referrerpolicy="no-referrer">
      </picture>
    <figcaption><span></span></figcaption></figure><p>故此，中國應該充分認識到，單靠自己的國產疫苗是無法完全走出疫情的，更是無法完全打開國門的。特別是中國早前不依靠疫苗，依靠封城，普篩，隔離等手段也成功控制住了疫情，目前中國本土的疫情也完全處於可控狀態，大可不必急於給中國民眾接種國產疫苗。因為以中國國產疫苗的實際表現來看，中國人的接種率就算達到了100%，也無法達成群體免疫，更何況任何一個群體都無法做到100%的疫苗施打率。因為一般認為群體免疫可能需要有8成完全防護的能力，以9成的疫苗有效率來計算，也要九成的人口完全施打才能達成。而中國國產疫苗的真實有效率大概在5到6成之間，是永遠無法使中國達到群體免疫的。故防疫面前，中國應該放棄國別成見，不要卡關，盡快批准復必泰的疫苗上市。</p><p>故此，中國應該盡快改變疫苗策略，不應該給民眾大規模接種國產疫苗，而應該大量進口或者代工有效率更高的復必泰或Moderna疫苗給國人施打。中國基礎設施完備，mRNA疫苗需要的較高運輸和冷藏條件應該不成問題。中國目前主要的國產疫苗雖然有效率差強人意，但防護住院和重症乃至死亡的有效率還是十分優秀，是緩解醫療資源壓力，拯救生命的利器。故此這類的疫苗應該優先給國內的高危人群，以及因為種種原因無法取得更高有效率的疫苗的國家施打，幫助他們緩解疫苗資源壓力。這類的國家和人群可在疫苗資源充足後再繼續施打更高有效率的疫苗。而中國作為外匯儲備豐富，國家財政實力雄厚，基礎設施建設完備的大國，在國內疫情控制良好的情況下又沒有急切施打疫苗的壓力，因此應該趁歐美各國已經逐漸完成大規模接種疫苗且Pfizer和Moderna等藥廠產能增加的情況下，儘量多購買它們的疫苗給國人施打。上海復星本就和BNT簽訂過代理協議，也應該積極尋求代工，擴大產能，提供國人需求。只有中國人大規模接種有效率高的疫苗，中國才能真正放心打開國門，重新連結世界。否則就是鏡花水月，自己關起門來宣布勝利罷了。</p><p><br></p><p><br></p><p><br></p>
